Publicado en NEJM el estudio IMPROVE-IT. Bajar el colesterol LDL a 50 mg/dl mejor que 70 mg/dl en prevención... http://t.co/dfUFtaZ9Qe
¡El IMPROVE-IT publicado! Bajar el LDLcolesterol a 50 mejor que a 70 para prevención secundaria de eventos vasculares http://t.co/T8mWnQfQ7y
IMPROVE-IT finally published! Less cholesterol is better http://t.co/T8mWnQfQ7y -7% cardiovascular events
#Ezetimibe Added to Statin Therapy after ACS http://t.co/G1nIzXKrBQ & editorial http://t.co/wWBbQnit62 (IMPROVE-IT)
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
http://t.co/aj6xSaH4e3 Un video de @NEJM explicando IMPROVE-IT http://t.co/Z0Q3rmrSkH
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
http://t.co/aj6xSaH4e3 Un video de @NEJM explicando IMPROVE-IT http://t.co/Z0Q3rmrSkH
Habemus IMPROVE-IT en @NEJM http://t.co/vVitbFtDtV @secardiologia Ya tardaba la publicacion... http://t.co/gGhSKDEctP
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Habemus IMPROVE-IT en @NEJM http://t.co/vVitbFtDtV @secardiologia Ya tardaba la publicacion... http://t.co/gGhSKDEctP
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Nu är den banne mig här. @NEJM-publikationen av Improve-it om värdet av extra kolesterolsänkning. http://t.co/85Evg64xfB Ping @EvidensJonas
Sin sorpresas en la publicación de IMPROVE-IT en NEJM http://t.co/w4QJtFTw5q
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
#Ezetimibe Added to Statin Therapy after ACS http://t.co/G1nIzXKrBQ & editorial http://t.co/wWBbQnit62 (IMPROVE-IT)
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Resultados IMPROVE-IT vía @NEJM:Ezetimibe+simva reduce eventos Cardiovasculares. LDL=50 en alto riesgo? http://t.co/O4qmcXtBFY
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
急性冠症候群後のスタチン+エゼチミブの効果を検討したDB-RCT。論文化されました。,複合心血管アウトカムは追跡6年でハザード比0.936[0.89 to 0.99]http://t.co/iW6TpVOsJn PDF http://t.co/ovvNw32rom
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
急性冠症候群後のスタチン+エゼチミブの効果を検討したDB-RCT。論文化されました。,複合心血管アウトカムは追跡6年でハザード比0.936[0.89 to 0.99]http://t.co/iW6TpVOsJn PDF http://t.co/ovvNw32rom
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes — NEJM http://t.co/WDZdTfnhay
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
@JadeBasaraba Definite JC candidate: IMPROVE-IT (finally) published online in @NEJM http://t.co/P3VpyON0G2
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
【IMPROVE-IT,ついに論文化。強化スタチン療法下のACS既往例へのエゼチミブ追加により,心血管系イベントは7年間で絶対リスク2%の有意減少。発がんに差なし:18144例ランダム化】 NEJM http://t.co/JeymRlISjT
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
$MRK IMPROVE-IT Data finally published in NEJM 6mo after AHA http://t.co/okxyCGZs86 Editorial http://t.co/19Psz1DlEr http://t.co/a1WvKhBvfQ
Results of IMPROVE-IT published online at NEJM today! http://t.co/d9CxHGfxpm
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Results of IMPROVE-IT published online at NEJM today! http://t.co/d9CxHGfxpm
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Results of IMPROVE-IT published online at NEJM today! http://t.co/d9CxHGfxpm
$MRK IMPROVE-IT Data finally published in NEJM 6mo after AHA http://t.co/okxyCGZs86 Editorial http://t.co/19Psz1DlEr http://t.co/a1WvKhBvfQ
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
I've been off the grid all day (seeing patients), but nice to see IMPROVE-IT out! http://t.co/ElVNNnSxPl
Main results of IMPROVE-IT have finally been published in NEJM. http://t.co/Y3BhlWNNI7 Nothing terribly new or exciting.
$MRK IMPROVE-IT Data finally published in NEJM 6mo after AHA http://t.co/okxyCGZs86 Editorial http://t.co/19Psz1DlEr http://t.co/a1WvKhBvfQ
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Results of IMPROVE-IT published online at NEJM today! http://t.co/d9CxHGfxpm
More LDL controversy: IMPROVE-IT suggests ezetimibe is beneficial, contradicting ENHANCE and ACC/AHA guidelines - http://t.co/w07d5fD1V5
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Main results of IMPROVE-IT have finally been published in NEJM. http://t.co/Y3BhlWNNI7 Nothing terribly new or exciting.
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
#Ezetimibe Added to Statin Therapy after ACS http://t.co/G1nIzXKrBQ & editorial http://t.co/wWBbQnit62 (IMPROVE-IT)
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
http://t.co/aj6xSaH4e3 Un video de @NEJM explicando IMPROVE-IT http://t.co/Z0Q3rmrSkH
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Habemus IMPROVE-IT en @NEJM http://t.co/vVitbFtDtV @secardiologia Ya tardaba la publicacion... http://t.co/gGhSKDEctP
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
http://t.co/aj6xSaH4e3 Un video de @NEJM explicando IMPROVE-IT http://t.co/Z0Q3rmrSkH
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
$MRK IMPROVE-IT Data finally published in NEJM 6mo after AHA http://t.co/okxyCGZs86 Editorial http://t.co/19Psz1DlEr http://t.co/a1WvKhBvfQ
Watch new Quick Take on IMPROVE-IT study on ezetimibe and CV outcomes. What you need to know, in < 2 mins. http://t.co/8PLOdUgrHd
Resultados del IMPROVE-IT http://t.co/k46neKzMgZ
IMPROVE IT Trial published in NEJM http://t.co/u1I58ZkykU http://t.co/KALgtRscCA
A non-statin (ezetimibe) reduces heart disease risk a bit (in 2/100 people) & supports low LDL http://t.co/0fDIKox0zi http://t.co/hDkC8kYlR9